Navigation Links
Novo Nordisk Appoints New Leader of North American Business
Date:9/4/2007

$2.1 billion in 2006. Under his leadership, Novo Nordisk has successfully launched the company's complete portfolio of modern insulin, earned a position as the diabetes care leader in the North American market and at the same time built a strong biopharmaceuticals business. Today, Novo Nordisk employs more than 3,000 people in the U.S.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 25,000 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO.' For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.


'/>"/>
SOURCE Novo Nordisk Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Imbalance In Gender Ratio Addressed By Religious Leaders
2. Religious Leaders condemn determination of sex in hospitals
3. Need For Social Churning Emphasized In CMC Meet On ‘Leadership In Healthcare
4. North-Eastern Leaders Of India Meet To Discuss HIV Problems
5. Cheerleaders run high risk of injury-US study
6. Muslim Leaders’ Help Sought To Discourage Smokin
7. Freedom Fighter And Orissa Congress Leader Dies Of Chest Pain
8. Religious Leaders Come In The Way Of Euthanasia
9. Learn From a Leader: Smitherman shares a personal story about his battle with drugs
10. NDP Leader in B.C. Diagnosed with Endometrial Cancer
11. India needs dental health leadership, says expert
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Heart Damage After Vascular Surgery Raises Death Risks 48779 1Heart Damage After Vascular Surgery Raises Death Risks 48779 2Tobacco Control Bill Heads to White House as Health Groups Cheer 48777 1Tobacco Control Bill Heads to White House as Health Groups Cheer 48777 2Tobacco Control Bill Heads to White House as Health Groups Cheer 48777 3WVU Doctor Works to Reduce Cancer Burden in Africa 48775 1WVU Doctor Works to Reduce Cancer Burden in Africa 48775 2